OBINUTUZUMAB
Obinutuzumab, is a humanised anti-CD20 monoclonal antibody. It can be used as a first-line treatment for chronic lymphocytic leukaemia in combination with chemotherapy or with venetoclax, as a first-line treatment for follicular lymphoma in combination with chemotherapy, and as treatment for relapsed or refractory follicular lymphoma in combination with bendamustine chemotherapy. Obinutuzumab is a monoclonal antibody used in the treatment of certain types of cancer. It belongs to a class of drugs known as CD20-directed cytolytic antibodies. This medication works by targeting and destroying certain cells in the immune system, specifically those expressing CD20, which is commonly found on the surface of B cells.Obinutuzumab is primarily indicated for the treatment of: -Chronic lymphocytic leukemia (CLL): Used in combination with other chemotherapy drugs for previously untreated CLL. -Follicular lymphoma: Administered in combination with chemotherapy for patients with untreated advanced-stage follicular lymphoma. -Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma.
IV solution; 25mg/mL (1000mg/40mL singleuse vial) Chronic Lymphocytic Leukemia :Adult Dosage Administer for 6 treatment cycles (28-day cycles) Cycle 1 Day 1: 100 mg IV Day 2: 900 mg IV Days 8 and 15: 1000 mg IV Cycles 2-6 Day 1: 1000 mg IV Follicular Lymphoma : Adult dosage Dosage regimen Cycle 1: 1000 mg IV on Days 1, 8, and 15 Cycles 2-6 or 2-8: 1000 mg IV on Day 1 If a complete or partial response is achieved, continue with obinutuzumab 1000 mg every 2 months as monotherapy for up to 2 years. -The dosage of obinutuzumab depends on the specific condition being treated and the patient's health status. It is typically administered intravenously by a healthcare professional.
Obinutuzumab is contraindicated in individuals with a known hypersensitivity to the drug or any of its components. Caution is advised in patients with active infections.
Paediatric: Data not sufficient Pregnancy: The drug can cause fetal harm when administered to a pregnant woman; advise females of reproductive potential to use effective contraception during treatment and for 6 months after the last dose Lactation: Unknown if distributed in human breast milk; because of the potential of serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment and for 6 months after the last dose. Elderly: Data not sufficient -Special precautions should be taken in patients with a history of hepatitis B infection, as obinutuzumab may reactivate the virus. Close monitoring is necessary, and antiviral prophylaxis may be required.
-Reaction during or shortly after the injection, tiredness, low white blood cell counts, diarrhea, constipation, muscle or joint pain, stuffy nose, sneezing,cough, and sore throat, hives, difficulty breathing, swelling of the face, lips, tongue, or throat, rash, fever, joint pain, fast heartbeats, chest pain, wheezing, problems with speech, thought, vision, or muscle movement, sudden warmth, redness, tingly feeling, chills, lightheadedness, nausea, headache, pounding in the neck or ears, tiredness, dizziness, diarrhea, vomiting, chest discomfort, easy bruising, unusual bleeding, purple or red spots under the skin, confusion, vision problems. -Common side effects of obinutuzumab include infusion reactions, low blood cell counts, fatigue, cough, and gastrointestinal symptoms. Serious but rare side effects may include infections, severe skin reactions, and cardiac issues. Patients should promptly report any unusual or severe symptoms to their healthcare provider.
-There are limited documented drug interactions with obinutuzumab. However, caution should be exercised when combining it with other immunosuppressive agents or medications that may affect the immune system. -Axicabtagene ciloleucel, brexucabtagene autoleucel, ciltacabtagene autoleucel, deferiprone, idecabtagene vicleucel, lisocabtagene maraleucel, palifermin, ropeginterferon alfa 2b, tisagenlecleucel
